Probiotics Mixture, Prohep: a Potential Adjuvant for Low-Dose Sorafenib in Metabolic Dysfunction–Associated Steatotic Liver Disease–Associated Hepatocellular Carcinoma Suppression Through Modulating Gut Microbiota DOI Creative Commons
Fangfei Zhang, Emily Kwun Kwan Lo, Congjia Chen

et al.

Probiotics and Antimicrobial Proteins, Journal Year: 2025, Volume and Issue: unknown

Published: May 23, 2025

Abstract Targeting gut microbiota is an innovative approach to mitigate the development of metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma (MASLD-HCC). This study aims investigate effects Prohep, a probiotic mixture, both as prophylactic measure and adjuvant therapy for low-dose sorafenib. A MASLD-HCC mice model was established by diethylnitrosamine (DEN) injection with feeding high-fat high-cholesterol (HFHC) diet. Gut microbiome profiles were later identified through shotgun sequencing. Our findings demonstrated that Prohep supplementation effectively suppressed in mice. protective effect attributed modulation increased production short-chain fatty acids (SCFAs), propionate, valerate. also activated AMPK, which decreased lipogenesis, reduced lipid uptake, enhanced antioxidant enzyme expressions. Additionally, cancer proliferation pathway PI3K/mTOR inhibited response treatment. As therapy, improved efficacy sorafenib, indicated tumor counts, alleviated inflammation, hepatic superoxide dismutase (SOD) expression. The combination led butyrate production, contributing overall therapeutic effects, thanks modulatory Prohep. These results underscore Prohep’s anti-tumorigenic properties its potential enhance outcomes sorafenib highlights importance developing effective neoadjuvant therapies long-term management strategies MASLD-HCC.

Language: Английский

Desulfovibrio in the Gut: The Enemy within? DOI Creative Commons
Sudha Singh, Amanda Carroll‐Portillo, Henry C. Lin

et al.

Microorganisms, Journal Year: 2023, Volume and Issue: 11(7), P. 1772 - 1772

Published: July 7, 2023

Desulfovibrio (DSV) are sulfate-reducing bacteria (SRB) that ubiquitously present in the environment and as resident commensal within human gastrointestinal tract. Though they minor residents of healthy gut, DSV opportunistic pathobionts may overgrow setting various intestinal extra-intestinal diseases. An increasing number studies have demonstrated a positive correlation between overgrowth (bloom) While relationship bloom disease pathology has not been clearly established, mounting evidence suggests causal role for these development. As most predominant genera SRB this review summarizes current knowledge regarding variety In study, we also discuss mechanisms by which contribute to pathology.

Language: Английский

Citations

94
Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease DOI Creative Commons
Xin Zhou, Xiaotao Shen, Jethro S. Johnson

et al.

Cell Host & Microbe, Journal Year: 2024, Volume and Issue: 32(4), P. 506 - 526.e9

Published: March 12, 2024

To understand the dynamic interplay between human microbiome and host during health disease, we analyzed microbial composition, temporal dynamics, associations with multi-omics, immune, clinical markers of microbiomes from four body sites in 86 participants over 6 years. We found that stability individuality are body-site specific heavily influenced by host. The stool oral more stable than skin nasal microbiomes, possibly due to their interaction environment. identify individual-specific commonly shared bacterial taxa, individualized taxa showing greater stability. Interestingly, dynamics correlate across sites, suggesting systemic host-microbial-environment interactions. Notably, insulin-resistant individuals show altered among microbiome, molecular markers, features, disrupted metabolic disease. Our study offers comprehensive views multi-site relationship

Language: Английский

Citations

49
Amelioration of obesity and inflammation by polysaccharide from unripe fruits of raspberry via gut microbiota regulation DOI
Yuzhe Huang,

Jingjing Hu,

Qijun Xia

et al.

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 261, P. 129825 - 129825

Published: Feb. 1, 2024

Language: Английский

Citations

18
Effects of intestinal Desulfovibrio bacteria on host health and its potential regulatory strategies: A review DOI

Heyi Zhou,

Dandan Huang,

Zetong Sun

et al.

Microbiological Research, Journal Year: 2024, Volume and Issue: 284, P. 127725 - 127725

Published: April 12, 2024

Language: Английский

Citations

17
Foodborne Carbon Dot Exposure Induces Insulin Resistance through Gut Microbiota Dysbiosis and Damaged Intestinal Mucus Layer DOI
Boya Zhang,

Xingpei Fan,

Hai‐Ning Du

et al.

ACS Nano, Journal Year: 2023, Volume and Issue: 17(6), P. 6081 - 6094

Published: March 10, 2023

Foodborne carbon dots (CDs), an emerging food nanocontaminant, are increasing risk factor for metabolic toxicity in mammals. Here, we report that chronic CD exposure induced glucose metabolism disorders via disruption of the gut–liver axis mice. 16s rRNA analysis demonstrated decreased abundance beneficial bacteria (Bacteroides, Coprococcus, and S24-7) increased harmful (Proteobacteria, Oscillospira, Desulfovibrionaceae, Ruminococcaceae), as well Firmicutes/Bacteroidetes ratio. Mechanistically, pro-inflammatory release endotoxin lipopolysaccharide, which induces intestinal inflammation mucus layer, activating systemic inducing hepatic insulin resistance mice TLR4/NFκB/MAPK signaling pathway. Furthermore, these changes were almost completely reversed by probiotics. Fecal microbiota transplantation from CD-exposed intolerance, damaged liver function, layer injury, inflammation, recipient However, microbiota-depleted exposed to CDs had normal levels biomarkers consistent with control mice, revealed gut dysbiosis contributes CD-induced inflammation-mediated resistance. Together, our findings attempted elucidate specific underlying mechanism. emphasized importance assessing hazards associated foodborne CDs.

Language: Английский

Citations

41
Hydrogen sulfide produced by the gut microbiota impairs host metabolism via reducing GLP-1 levels in male mice DOI
Qingqing Qi, Huijie Zhang, Zheyu Jin

et al.

Nature Metabolism, Journal Year: 2024, Volume and Issue: 6(8), P. 1601 - 1615

Published: July 19, 2024

Language: Английский

Citations

16
Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3 DOI Creative Commons

Guifang Li,

Huan Liu,

Yangmeng Yu

et al.

EBioMedicine, Journal Year: 2024, Volume and Issue: 102, P. 105041 - 105041

Published: March 13, 2024

BackgroundChemoresistance is a critical factor contributing to poor prognosis in clinical patients with cancer undergoing postoperative adjuvant chemotherapy. The role of gut microbiota mediating resistance tumour chemotherapy remains be investigated.MethodsPatients CRC were categorised into benefit responders (CBR) and no (NCB) based on efficacy. Differential bacterial analysis using 16S rRNA sequencing revealed Desulfovibrio as distinct microbe between the two groups. Employing syngeneic transplantation model, we assessed effect by measuring burden, weight, Ki-67 expression. We further explored mechanisms underlying compromised chemotherapeutic efficacy metabolomics, western blotting, colony formation, cell apoptosis assays.FindingsIn comparison, was more abundant NCB group. In vivo experiments that colonisation weakened FOLFOX. Treatment desulfuricans elevates serum S-adenosylmethionine (SAM) levels. Interestingly, SAM reduced sensitivity cells FOLFOX, thereby promoting growth tumours. These suggest promotes metastasis driving expression methyltransferase-like 3 (METTL3).InterpretationA high abundance intestines indicates therapeutic outcomes for neoadjuvant FOLFOX CRC. drives manifestation METTL3 CRC, increasing concentration SAM.FundingThis study supported Wuxi City Social Development Science Technology Demonstration Project (N20201005).

Language: Английский

Citations

14
The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota DOI Creative Commons
Gabriel Henrique Hizo, Pabulo Henrique Rampelotto

Life, Journal Year: 2024, Volume and Issue: 14(2), P. 239 - 239

Published: Feb. 8, 2024

Recent studies have shown the promising potential of probiotics, especially bacterial genus Bifidobacterium, in treatment liver diseases. In this work, a systematic review was conducted, with focus on that employed advanced Next Generation Sequencing (NGS) technologies to explore Bifidobacterium as probiotic for treating pathologies such Non-Alcoholic Fatty Liver Disease (NAFLD), Steatohepatitis (NASH), Alcoholic (ALD), Cirrhosis, and Hepatocelullar Carcinoma (HCC) its impact microbiota. Our results indicate is safe effective lesions. It successfully restored balance intestinal microbiota improved biochemical clinical parameters NAFLD, ALD, Cirrhosis. No significant adverse effects were identified. While more research needed establish efficacy NASH HCC, evidence suggests managing

Language: Английский

Citations

10
Diversity and Comparison of Intestinal Desulfovibrio in Patients with Liver Cirrhosis and Healthy People DOI Creative Commons
Gexue Lu, Yu Zhang, Yilin Ren

et al.

Microorganisms, Journal Year: 2023, Volume and Issue: 11(2), P. 276 - 276

Published: Jan. 20, 2023

Desulfovibrio belongs to Sulfate-reducing bacteria (SRB), which are widely present in anaerobic environments, including the human gut. has been associated with many diseases, chronic liver disease. However, characteristics and difference of from fecal samples healthy volunteers (HV) patients cirrhosis (LC) have not fully elucidated. Here, we isolated feces 6 HV 9 LC, 88 strains were obtained. In HV, 55% D. desulfuricans, followed by intestinalis (15%), simplex (11%), piger (9%), legallii (4%), Cupidesulfovibrio oxamicus (4%) fairfieldensis (2%). only desulfuricans (60%) C. (40%) LC. Our results suggest that there was a significant desulfurization ability H2S production different Desulfovibrio. Furthermore, found LC generally had higher hydrogen sulfide capacity, gastrointestinal tolerance, levels antibiotic resistance than same species HV. findings suggested may be occurrence development cirrhosis.

Language: Английский

Citations

17
Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease DOI Creative Commons

Jakub Rochoń,

Piotr Kalinowski, Ksenia Szymanek-Majchrzak

et al.

World Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 30(23), P. 2964 - 2980

Published: June 20, 2024

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a hepatic manifestation of the metabolic syndrome. It one most common diseases worldwide and shows increasing prevalence rates in countries. MAFLD progressive with severe cases presenting as advanced fibrosis or cirrhosis an increased risk hepatocellular carcinoma. Gut microbiota play significant role pathogenesis progression by disrupting gut-liver axis. The mechanisms involved maintaining axis homeostasis are complex. One critical aspect involves preserving appropriate intestinal barrier permeability levels lumen metabolites to ensure functionality. An increase induces endotoxemia that leads steatohepatitis. Moreover, alterations absorption various can affect metabolism induce steatosis fibrosis. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) class drugs developed for treatment type 2 diabetes mellitus. They also commonly used combat obesity have been proven be effective reversing steatosis. reported this effect include improved regulation glycemia, reduced lipid synthesis, β-oxidation free acids, induction autophagy cells. Recently, multiple peptide introduced expected effectiveness treatment. A modulation gut has observed use these may contribute amelioration MAFLD. This review presents current understanding development members GLP-1 RA family pleiotropic agents

Language: Английский

Citations

8